Determine MTD, Evaluate Efficacy and Safety of Genexol®-PM Plus Carboplatin With Advanced Ovarian Cancer

• Status: Completed
• Trial end date: 2009-06-01
• Target enrollment: 0
• Participant gender: Female

Summary

The purpose of this study is to determine the maximum tolerated dose of Genexol®-PM plus Carboplatin and evaluate the efficacy and safety of Genexol®-PM plus Carboplatin regimen in subjects with advanced ovarian cancer.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Samyang Biopharmaceuticals Corporation
• Treatments: Carboplatin

Criteria

Inclusion Criteria:

• Women ≥ 18 years old.

• Signed informed consent before inclusion.

• Subjects who have histologically or cytologically confirmed advanced epithelial ovarian cancer.(FIGO IIIB-IV)

• Subjects who have measurable disease by RECIST after debulking surgery.

• ECOG performance status of 0, 1, or 2.

• Estimated life expectancy of more than 6 months

• Subjects who have the clinically acceptable function of blood, kidney and liver at screening visit

• Hb ≥ 10g/dl

• ANC ≥ 1.5×10^9/L

• Platelet Count ≥ 100×10^9/L

• Serum total bilirubin ≤ 1.5×ULN

• Serum AST and ALT ≤ 2.5×ULN

• Serum ALP ≤ 2.5×ULN

• Serum creatinine ≤ 1.5×ULN

Exclusion Criteria:

• Subjects who have received chemotherapy for ovarian cancer other than debulking surgery.

• Subjects who have a history of radiotherapy to pelvis or abdominal cavity

• Subjects who receive immunotherapy or hormonal therapy for ovarian cancer

• Subjects who have other malignancies within the past 5 years

• Subjects who have had a major surgery other than debulking surgery within 2 weeks prior to the screening/baseline visit

• Subjects who have a history of metastasis or currently have a metastasis to the central nervous system(CNS)

• Subjects who have a preexisting sensory or motor neuropathy of grade ≥ 1 based on NCI CTCAE V3.0

• Subjects who have serious medical condition

• Uncontrolled or severe cardiovascular disease(Ischemic heart disease, myocardial infarction within the last 6 months, congestive heart failure)

• Uncontrollable infection

• Previous allergic reactions in connection with paclitaxel and carboplatin

• Subjects who participate another clinical trial within the last 4 weeks before inclusion